Vietnam Minister of Planning and Investment visits AstraZeneca China

Vietnam Minister of Planning and Investment visits AstraZeneca China

A delegation led by Minister for Planning and Investment Nguyen Chi Dung has visited the AstraZeneca Global (R&D) China Centre.
Utilising robotic microscopes in surgery

Utilising robotic microscopes in surgery

Medical experts gathered at a seminar in Hanoi on March 23 to discuss the use of robotic microscope surgery.
Healthcare service quality must meet global standards

Healthcare service quality must meet global standards

Vietnam is actively improving the quality of medical services at hospitals towards meeting international standards, aiming to engage foreigners for medical examination and treatment here.
Hanoi French Hospital acquires advanced surgical microscope

Hanoi French Hospital acquires advanced surgical microscope

Hanoi French Hospital has acquired the latest state-of-the-art surgical microscope system from Carl Zeiss.
Connecting rare traits into pathways for rare disease patients

Connecting rare traits into pathways for rare disease patients

Diagnosing, treating and caring for patients with rare diseases is a big challenge no matter where they are in the world, so various stakeholders have teamed up to support them.
Increasing private investment in healthcare – A long journey ahead

Increasing private investment in healthcare – A long journey ahead

While making efforts to attract investment, the healthcare sector yet to meet its expectations. Nguyen Thi Lien Huong, Deputy Minister of Health, talked with VIR’s Bich Thuy the next steps ahead to make improvements.
Strengthening partnership to better eye care in Vietnam

Strengthening partnership to better eye care in Vietnam

Leading experts and market developers joined VIR’s talk show on February 18 to discuss the advancement of medical devices for eye care in Vietnam, and how stakeholders can join hands to offer a fresh view among society.
Global pharma expects bumper year

Global pharma expects bumper year

Increasing footprints in Vietnam in 2023, multinational corporations continue to eye stronger local partnerships to bring more new innovative medicines and vaccines to the local market in 2024 and beyond.
Legal landscape adjusted for global pharma groups

Legal landscape adjusted for global pharma groups

Multinational corporations operating in Vietnam are expected to benefit from new legal changes in the months to come, after years of delay.
A more conducive environment needed for investors

A more conducive environment needed for investors

Last year marked Pharma Group’s 25-year journey of partnership in Vietnam. That year was even more significant for healthcare as we have witnessed several key laws issued with great improvements, notably the Law on Bidding and the Law on Medical Examination and Treatment.
AstraZeneca, VYPA sign MOU to enhance healthcare in Vietnam

AstraZeneca, VYPA sign MOU to enhance healthcare in Vietnam

AstraZeneca Vietnam and the Vietnam Young Physicians Association have signed an MoU on future cooperation.
Novartis defends Vildagliptin patent

Novartis defends Vildagliptin patent

Novartis has successfully defended its patent for Vildagliptin and is committed to its mission of innovation in the Vietnamese healthcare sector.
Local pharma giants reaping rewards with new strategies

Local pharma giants reaping rewards with new strategies

While the shift to the hospital channel brought fruitful results for major pharma players in Vietnam in 2023, competition is forecast to heat up in the future.
Fluctuations felt in pharma retail sphere

Fluctuations felt in pharma retail sphere

The race in Vietnam’s pharmaceutical retail industry is becoming a tough arena for major players.
The trends and driving factors in OTC and ETC drugs

The trends and driving factors in OTC and ETC drugs

In Vietnam, the primary channels for medicine distribution are over-the-counter (OTC) and prescribed drugs. According to Vietnam Credit’s recent report on the country’s pharmaceutical industry, prescribed drugs channels constitute 70 per cent of the medicine market, and OTC channels constituting the remainder.
|< < 1 2 3 4 > >|